tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target
PremiumRatingsCytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target
27d ago
CytomX Therapeutics announces business update, 2026 milestones
Premium
The Fly
CytomX Therapeutics announces business update, 2026 milestones
28d ago
Buy Rating for CytomX Therapeutics’ CX-2051 Based on Promising Colorectal Cancer Treatment Potential
Premium
Ratings
Buy Rating for CytomX Therapeutics’ CX-2051 Based on Promising Colorectal Cancer Treatment Potential
2M ago
CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
PremiumThe FlyCytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
3M ago
CytomX Therapeutics Advances CX-2051 Study in Solid Tumors
Premium
Company Announcements
CytomX Therapeutics Advances CX-2051 Study in Solid Tumors
3M ago
Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051
Premium
Ratings
Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051
3M ago
CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
PremiumRatingsCytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
4M ago
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100